l.wikstrom
TL2 Moderator · Osijek
Contributes reviews on supplier material. Based in Osijek.
Joined 20 February 2025 · last posted 17h
83 posts, newest first. Showing up to 150.
-
How shortages have affected compounding permissions — does this still hold? Replied, post #32 · Access › Shortages · 27 Jul 2026 · 18 likes Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.
-
Insomnia at a dose step: reported experiences — the long version Replied, post #52 · Wellbeing › Sleep · 27 Jul 2026 · 0 likes Worth separating two things that post #48 runs together. Apnoea monitoring: if you have diagnosed or suspected sleep apnoea, periodic monitoring (annually) during…
-
What a good consultation looks like from the other side Replied, post #61 · Clinical › Prescriber conversations · 21 Jul 2026 · 3 likes Picking up post #58: that is the part I would want checked first. Understanding stopping rules: what would prompt stopping the compound? Adverse effect, lack of benefit…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #50 · Start Here › Welcome · 16 Jul 2026 · 18 likes Off-topic posts that do not belong here belong in the Lounge instead. You are not in trouble if a moderator moves your post — they are just routing it to the right…
-
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still… Replied, post #43 · Compounds › Retatrutide · 14 Jul 2026 · 0 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
-
How much context is too much context in a first post? Replied, post #72 · Start Here › How to Ask · 10 Jul 2026 · 15 likes I read post #70 twice before replying, because I had assumed the opposite. Five questions in one post gets you one answer: the easiest one, usually not the one you…
-
Insurance and replacement policies, compared Replied, post #71 · Sourcing › Logistics · 7 Jul 2026 · 10 likes Coming back to post #69, because the follow-up matters more than the original answer. Customs holds: if a parcel is held at customs and you can contact customs…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #40 · Compounds › Retatrutide · 5 Jul 2026 · 7 likes Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The…
-
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #2 · Analytics › COA interpretation · 2 Jul 2026 · 9 likes Water content (residual moisture) matters: lyophilised peptide is not dry. A few percent water is normal. The difference between a TFA salt and an acetate salt can be…
-
Second pass at: When your prescriber and the evidence disagree Replied, post #42 · Clinical › Prescriber conversations · 28 Jun 2026 · 4 likes What to bring: copies of relevant lab results, pharmacy records (to confirm doses actually taken), and records of any adverse effects you have experienced with other…
-
Peak-to-trough ratio at steady state for a weekly agent — the long version Replied, post #35 · Pharmacology › Pharmacokinetics · 27 Jun 2026 · 6 likes This follows post #32 rather than contradicting it. SNAC (the oral bioavailability enhancer): sodium N-(8-[2-hydroxybenzoyl]amino) caprylate transiently raises gastric…
-
Osteoarthritis and mechanical versus metabolic improvement Replied, post #4 · Clinical › Comorbidities · 26 Jun 2026 · 9 likes Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct…
-
Angle of injection and whether 90 degrees is always right — the long version Replied, post #30 · Practice › Administration · 23 Jun 2026 · 4 likes Leak-back after withdrawal: a small amount of liquid on the skin after withdrawal is ordinary. Whether you lost a "meaningful" dose depends on concentration and your…
-
When a dose reduction is the correct response to a side effect Replied, post #29 · Practice › Dosing & titration · 13 Jun 2026 · 29 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Reading a trial's population section before its results Replied, post #106 · Evidence › Trials · 9 Jun 2026 · 2 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Racemisation and why it is invisible to a mass measurement Replied, post #8 · Analytics › Impurities & related substances · 8 Jun 2026 · 0 likes Truncation products: fragments from incomplete synthesis or from degradation. They elute quite differently from the intact peptide because they are much smaller and…
-
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #81 · Practice › Storage & stability · 7 Jun 2026 · 2 likes post #80 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather…
-
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #79 · Sourcing › Red flags · 6 Jun 2026 · 10 likes This follows post #76 rather than contradicting it. Unresponsiveness: a supplier that does not reply to reasonable requests for documentation or clarification is…
-
Specificity, linearity, accuracy, precision, range, robustness — with real criteria Replied, post #26 · Analytics › Method validation · 5 Jun 2026 · 10 likes post #25 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #72 · Evidence › Journal club · 31 May 2026 · 0 likes SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the cardiovascular evidence to the oral formulation. Note that oral bioavailability is lower…
-
Reading a trial's population section before its results Replied, post #50 · Evidence › Trials · 24 May 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Blind submission and why it changes minds — the long version Replied, post #87 · Sourcing › Independent verification · 20 May 2026 · 13 likes Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth…
-
Five questions in one post gets you one answer — how to split them Replied, post #74 · Start Here › How to Ask · 7 May 2026 · 4 likes post #73 answers the question as asked. The question underneath it is different. Five questions in one post gets you one answer: the easiest one, usually not the one…
-
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #131 · Pharmacology › Pharmacokinetics · 6 May 2026 · 0 likes Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that,…
-
Journal club: is percentage weight change the right endpoint? Replied, post #115 · Evidence › Journal club · 29 Apr 2026 · 0 likes Coming back to post #113, because the follow-up matters more than the original answer. STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #39 · Evidence › Journal club · 15 Apr 2026 · 25 likes SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes. The first outcome trial in people without diabetes, which decoupled the cardiovascular…
-
Follow-up: Reconciling a label claim with a content assay Replied, post #10 · Analytics › COA interpretation · 15 Mar 2026 · 8 likes Reading old certificates: if a certificate is dated years ago, the lot it describes might be old. That is not automatically a problem but it is worth noting. Fresh…
-
[2026 update] What a good consultation looks like from the other side Replied, post #19 · Clinical › Prescriber conversations · 4 Mar 2026 · 1 like Asking about monitoring: understand what lab work will be done, how often, and what you will be monitored for. A plan is better than ad-hoc monitoring.
-
Personal import allowances, compared — a second dataset Replied, post #79 · Access › International · 4 Mar 2026 · 13 likes Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
-
Choosing a concentration on purpose rather than by accident Replied, post #2 · marked as the solution · Practice › Reconstitution · 25 Feb 2026 · 8 likes Coming back to the opening post, because the follow-up matters more than the original answer. Why "add 2 mL" is not an instruction: the powder in the vial takes up…
-
[2026 update] Confounding by indication, explained with a concrete example Replied, post #81 · Evidence › Study critique · 24 Feb 2026 · 3 likes Building consensus on which criticisms matter: if everyone agrees that the sample size is small but only you think that affects the conclusion, maybe your criticism is…
-
Second pass at: Which categories are strict and which are relaxed, honestly Replied, post #16 · Start Here › Welcome · 22 Feb 2026 · 0 likes Your introduction is well framed. You have given enough context that people can actually answer. That is rarer than it sounds and it matters more than it sounds.
-
Second pass at: Metformin co-administration and additive GI effects Replied, post #42 · Practice › Interactions · 31 Jan 2026 · 5 likes Coming back to post #40, because the follow-up matters more than the original answer. Insulin interaction: semaglutide and tirzepatide are not contraindicated with…
-
Specificity, linearity, accuracy, precision, range, robustness — with real criteria — a… Replied, post #59 · Analytics › Method validation · 29 Jan 2026 · 0 likes Worth separating two things that post #55 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
-
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #85 · Clinical › Special populations · 26 Jan 2026 · 29 likes Hepatic impairment: less is known about dosing in significant liver disease than in kidney disease. Extreme caution applies because the liver metabolises a large…
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #68 · Clinical › Special populations · 24 Jan 2026 · 23 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
A plateau that disappeared when I changed how I measured — the long version Replied, post #3 · Outcomes › Progress reports · 24 Jan 2026 · 5 likes Medication changes: escalating dose, or adding or removing other medications, can affect the rate of weight loss. Documenting medication changes alongside weight makes…
-
A pen that felt like it delivered nothing: diagnosing it afterwards Replied, post #39 · Devices › Pens & autoinjectors · 22 Jan 2026 · 3 likes Injection duration: most pens deliver the dose over several seconds. Holding the button down for the full duration ensures complete delivery. Releasing early can result…
-
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #98 · Compounds › Oral incretins · 18 Dec 2025 · 10 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
DXA precision and the least significant change for lean mass Replied, post #55 · Outcomes › Body composition · 9 Dec 2025 · 33 likes I read post #53 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say…
-
Tracking a preprint to publication: a worked example Replied, post #85 · Evidence › Preprints · 8 Dec 2025 · 2 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
When to stop reading forums, including this one Replied, post #59 · Wellbeing › Mental health · 8 Dec 2025 · 18 likes Body image and weight loss: large weight loss changes a person's relationship with their body in ways that can be psychologically complex. Some of that is positive;…
-
Reading SURMOUNT-1 without the press release Replied, post #90 · Compounds › Tirzepatide · 5 Dec 2025 · 1 like SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
-
Run-in periods and the population they select Replied, post #31 · Evidence › Trials · 5 Dec 2025 · 4 likes I read post #29 twice before replying, because I had assumed the opposite. Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the…
-
Cross-border purchase rules within the EU Replied, post #45 · Regional › European Union · 27 Nov 2025 · 4 likes This follows post #42 rather than contradicting it. Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation…
-
Coming back to: Injection-site reactions: describing them precisely enough to be useful Replied, post #25 · Practice › Side effects · 25 Nov 2025 · 14 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #61 · Compounds › Other compounds · 24 Nov 2025 · 2 likes post #60 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather…
-
Lurking for two months before posting: was that the right call? Replied, post #65 · Start Here › Welcome · 20 Nov 2025 · 2 likes post #64 is right about the mechanism and I think understates the practical bit. Off-topic posts that do not belong here belong in the Lounge instead. You are not in…
-
Pen dose counters: what a click does and does not guarantee Replied, post #113 · Devices › Pens & autoinjectors · 20 Nov 2025 · 27 likes Dose counters: pens show the remaining number of doses. When the counter reaches zero, the pen is empty and cannot deliver more. Noting the counter before injection…
-
Long-time reader, first-time poster Replied, post #6 · Lounge › Introductions · 5 Nov 2025 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Second pass at: Programming during a large energy deficit Replied, post #57 · Nutrition & Training › Resistance training · 28 Oct 2025 · 31 likes Coming back to post #55, because the follow-up matters more than the original answer. Programming while losing weight quickly: realistic expectations are crucial.…
-
Waist circumference technique and its repeatability Replied, post #8 · Outcomes › Progress reports · 18 Oct 2025 · 0 likes post #7 answers the question as asked. The question underneath it is different. Plateaus and resets: if weight loss stalls and then resumes, that is ordinary. It is not…
-
Compounds this community declines to help with, and why Replied, post #85 · Compounds › Other compounds · 8 Oct 2025 · 15 likes Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that…
-
Trust level 3 requirements: a clarification Replied, post #11 · Meta › Announcements · 8 Oct 2025 · 0 likes Implementation timeline: announcements include when a change takes effect. Marking the date helps you know whether the change is already in effect.
-
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #74 · Compounds › Cagrilintide & amylin analogues · 4 Oct 2025 · 2 likes Coming back to post #72, because the follow-up matters more than the original answer. The CagriSema phase 2 paper: a fixed combination of the two components in one…
-
Pinch or no pinch, and how needle length changes the answer Replied, post #81 · Practice › Administration · 27 Sep 2025 · 16 likes Leak-back after withdrawal: a small amount of liquid on the skin after withdrawal is ordinary. Whether you lost a "meaningful" dose depends on concentration and your…
-
Substitution between formats during a shortage Replied, post #63 · Access › Shortages · 25 Sep 2025 · 0 likes This follows post #60 rather than contradicting it. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add…
-
Titles that describe the question, not the situation — what changed since Replied, post #26 · Start Here › How to Ask · 19 Sep 2025 · 5 likes Avoid "any advice?" at the end. It is so generic that people do not know which part of the post it refers to. Pick the specific part and ask that specific question…
-
Research-use-only labelling: what it means and what it does not Replied, post #33 · Sourcing › Regulatory · 13 Sep 2025 · 4 likes Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The…
-
Pooling trials with different estimands — what changed since Replied, post #12 · Evidence › Meta-analyses · 11 Aug 2025 · 0 likes Publication bias: what did not get published? Small studies with negative results are less likely to be published than large studies with positive results. A forest…
-
Coming back to: What published stability data actually covers, and what it does not Replied, post #107 · Practice › Storage & stability · 7 Aug 2025 · 0 likes post #106 answers the question as asked. The question underneath it is different. Freeze-thaw: some peptide solutions tolerate freezing poorly because ice crystals…
-
How to research a compound with no human data without deceiving yourself Replied, post #50 · Compounds › Other compounds · 1 Aug 2025 · 2 likes This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits…
-
Comparing my trajectory with the trial curves, carefully Replied, post #29 · Outcomes › Progress reports · 28 Jul 2025 · 2 likes Picking up post #26: that is the part I would want checked first. Plateaus and resets: if weight loss stalls and then resumes, that is ordinary. It is not evidence that…
-
High-resolution MS on aggregates and what it can see Replied, post #27 · Analytics › Mass spectrometry · 21 Jul 2025 · 0 likes Sample matrix effects: if a sample is dissolved in a complex matrix, other compounds in the matrix can suppress the peptide signal. Clean samples give higher…
-
Repeatability versus intermediate precision Replied, post #4 · Analytics › Method validation · 16 Jun 2025 · 26 likes post #3 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Pre-registering a personal experiment, seriously Replied, post #69 · Research Methods › N-of-1 designs · 31 May 2025 · 14 likes Confounding in personal experiments: other things change when you start a medication (season, exercise, diet, stress). Documenting those confounders helps you…
-
Reconstituting a multi-strength kit without mixing yourself up Replied, post #70 · Practice › Reconstitution · 13 May 2025 · 12 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Follow-up: History of disordered eating and why it changes the conversation Started this topic · Clinical › Special populations · 21 Apr 2025 · 7 likes Posting this under the heading it deserves: History of disordered eating and why it changes the conversation Everything below is what sits behind that. General…
-
Validating a calculator against hand arithmetic — what changed since Replied, post #20 · Data & Tools › Calculators · 17 Apr 2025 · 4 likes Reconstitution calculator: enter vial mass, final volume target, and the calculator tells you concentration and syringe mark for a given dose. Useful for…
-
Retatrutide dose escalation in the published trials Replied, post #30 · Compounds › Retatrutide · 20 Mar 2025 · 1 like I read post #28 twice before replying, because I had assumed the opposite. Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises…
-
Preservatives: function, testing, and limits Replied, post #18 · Pharmacology › Formulation chemistry · 9 Mar 2025 · 21 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #61 · Devices › Cold chain · 3 Mar 2025 · 23 likes Temperature excursions: brief excursions above 8 °C are tolerable for most compounds. Hours to a day at room temperature is usually acceptable. Days to weeks at room…
-
SNAC and the mechanism of oral peptide absorption — the long version Replied, post #25 · Compounds › Oral incretins · 25 Jan 2025 · 5 likes On post #21 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
Oxidation pathways for methionine and tryptophan Replied, post #55 · Analytics › Impurities & related substances · 30 Dec 2024 · 11 likes Disulfide formation: if a peptide contains cysteine, it can form disulfide bonds with itself or with other molecules. Under oxidising conditions multiple species…
-
[2026 update] How to read a forest plot, properly, from scratch Replied, post #3 · Evidence › Trials · 25 Nov 2024 · 8 likes Picking up post #2: that is the part I would want checked first. Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method…
-
Turnaround times and what they mean for a decision — one year on Replied, post #13 · Sourcing › Independent verification · 11 Nov 2024 · 0 likes I read post #11 twice before replying, because I had assumed the opposite. Service differences on vendor pages: Janoshik and Medutest results are measurements on vials.…
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #91 · Clinical › Prescriber conversations · 2 Nov 2024 · 1 like Discussing off-label dosing: if you want to dose differently than the label specifies (slower titration, higher final dose), discussing that explicitly and…
-
Second pass at: Hoarding and why it makes a shortage worse Replied, post #117 · Access › Shortages · 13 Oct 2024 · 0 likes On post #113 — agreed on the reasoning, with one qualification. Supply interruptions: official shortage notices are published by regulatory agencies. That is the…
-
Hypertension improvement and when medication needs revisiting — a second dataset Replied, post #28 · Clinical › Comorbidities · 13 Oct 2024 · 4 likes On post #24 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
Circumference measurements as a poor man's composition estimate Replied, post #30 · Outcomes › Body composition · 30 Jul 2024 · 18 likes Coming back to post #28, because the follow-up matters more than the original answer. Resting metabolic rate: body composition affects metabolic rate. As fat mass…
-
Second pass at: Retatrutide dose escalation in the published trials Replied, post #17 · Compounds › Retatrutide · 16 Jul 2024 · 11 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
-
How this community labels and discusses unrefereed work Replied, post #42 · Evidence › Preprints · 26 Jun 2024 · 0 likes Worth separating two things that post #38 runs together. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather…
-
The mass-error checker and its intended scope Replied, post #2 · Data & Tools › Calculators · 18 May 2024 · 7 likes Precision and significant figures: the calculators do not round to match your input precision. If you input values to one decimal place, the output might have more. Use…